Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP)
2015-003878-33Phase 2Completed
- Sponsor
- Savara
- Start
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune pulmonary alveolar proteinosis (aPAP) and pulmonary alveolar proteinosis (PAP) comparing Molgramostim inhalation with Placebo inhalation (2 arms). Started Oct 2015; status: completed.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)pulmonary alveolar proteinosis (PAP)
Beyond the preview
Go deeper on 2015-003878-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003878-33.